APAC Anxiety Disorder Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Disorder, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$2.31 BnPlaceholder estimate
Estimate 2025$2.40 Bn20.6% of the global market
Projected 2034$3.39 Bn 41.1%Adds $986.3 Mn over 9 forecast years
CAGR 2025–20343.9%Faster than 1% of 180 Pharmaceuticals markets here
Key players5
APAC is 20.56% of the global market.
Among regions, the largest is North America at $6.08 Bn.
Pfizer Inc., Eli Lilly and Company, Viatris, Lundbeck, MindMed (see all)
Active clinical trials
255 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Anxiety Disorder Drugs Market Analysis Executive Summary
Anxiety disorder drugs treat generalised anxiety, panic and social anxiety with antidepressants, buspirone and other medicines.
Key segments of the anxiety Disorder Drugs market include drug class (SSRIs, SNRIs and Benzodiazepines) and disorder (Generalized Anxiety, Panic Disorder and Social Anxiety).
Asia Pacific Anxiety Disorder Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Anxiety Disorder Drugs Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the anxiety Disorder Drugs market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the anxiety Disorder Drugs market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the anxiety Disorder Drugs market.
Competitive Landscape for Anxiety Disorder Drugs Market in APAC
The anxiety Disorder Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Anxiety Disorder Drugs Market in APAC
Anxiety Disorder Drugs in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 255 studies on Anxiety Disorder Drugs that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for anxiety Disorder Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Disorder
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Pfizer
7.2 Eli Lilly and Company
7.3 Viatris
7.4 Lundbeck
7.5 MindMed
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The anxiety Disorder Drugs market can be segmented based on various criteria, including drug class, disorder and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Anxiety Disorder Drugs right now, from free public sources.
Clinical trials
255 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Anxiety Disorder Drugs market in Asia Pacific?
Placeholder estimate: about $2.40 Bn in 2025, rising to about $3.39 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Anxiety Disorder Drugs market in Asia Pacific growing?
Placeholder estimate: about 3.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Anxiety Disorder Drugs market report cover?
The report splits the market by drug class (SSRIs, SNRIs, Benzodiazepines, Buspirone and more), disorder (Generalized Anxiety, Panic Disorder, Social Anxiety) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Anxiety Disorder Drugs market?
Key players include Pfizer Inc., Eli Lilly and Company, Viatris, Lundbeck and MindMed.
What is driving the Anxiety Disorder Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the anxiety Disorder Drugs market. Governments and employers are investing more in mental health care.
How many clinical trials on Anxiety Disorder Drugs are running in Asia Pacific?
255 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Anxiety Disorder Drugs?
PubMed lists 5,079 papers on Anxiety Disorder Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.